Results 111 to 120 of about 1,866 (169)

Summary of Research: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Rheumatology and Therapy
This Summary of Research summarises results from the BE OPTIMAL (NCT03895203) and BE COMPLETE (NCT03896581) studies and their open-label extension, BE VITAL (NCT04009499).
Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates   +13 more
doaj   +1 more source

Successful treatment of severe acrodermatitis continua of hallopeau with Bimekizumab: A case report

SAGE Open Medical Case Reports
Acrodermatitis continua of Hallopeau is a rare form of pustular psoriasis affecting the acral fingers and toes, characterized by recurrent eruptions of sterile pustules that lead to significant pain and potentially irreversible destruction of the nail ...
Lily Xu, Kai Li, Eric L. Mutter, Annie Langley   +3 more
semanticscholar   +1 more source

Short-term efficacy of biologics targeting the IL-17/IL-23 axis in scalp, nail, and palmoplantar psoriasis: a network meta-analysis of randomized controlled trials

Frontiers in Immunology
BackgroundScalp, nail, and palmoplantar psoriasis are termed “difficult-to-treat sites” owing to their unique anatomical features and therapeutic resistance, substantially impairing patient quality of life.
Shouxu Zhang, Shouxu Zhang, TszLeong Lam, TszLeong Lam, Yue Du, Yue Du, Xiaoxuan Chen, Xiaoxuan Chen, Haomin Zhang, Haomin Zhang, Lingling Li, Guangzhong Zhang   +11 more
doaj   +1 more source

Bimekizumab in the Treatment of Axial Spondyloarthritis and Psoriatic Arthritis: A New Kid on the Block

International Journal of Molecular Sciences
The interleukin (IL)-17 family encompasses six structurally related pro-inflammatory cystine knot proteins, designated as IL-17A to IL-17F. Over the last decades, evidence has pointed to its role as a critical player in the development of inflammatory ...
J. Sarrand, L. Baglione, C. Bouvy, M. Soyfoo   +3 more
semanticscholar   +1 more source

Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials

Dermatology and Therapy
Introduction Psoriasis in high-impact areas, including the scalp, nails, palms, and soles, can disproportionately impair patient quality of life. Here, we evaluate the 2-year efficacy of bimekizumab treatment in patients with moderate to severe plaque ...
Joseph F. Merola, Alice B. Gottlieb, Andreas Pinter, Boni Elewski, Melinda Gooderham, Richard B. Warren, Stefano Piaserico, Krista Wixted, Nancy Cross, Nicola Tilt, Susanne Wiegratz, Ulrich Mrowietz   +11 more
doaj   +1 more source

The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F ...
Joshua Burshtein, Ken Gordon, Mark Lebwohl, Raj Chovatiya, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Robert Kalb, Joseph F. Merola, Mona Shahriari, Neil J. Korman   +11 more
core   +1 more source

Association Between Bimekizumab’s Clinical Response and Patient-Reported Benefits on Health-Related Quality of Life: Results from BE HEARD I and II

Dermatology and Therapy
Introduction Hidradenitis suppurativa (HS) is a chronic skin disease that greatly affects patients’ health-related quality of life (HRQoL). Bimekizumab, a humanised monoclonal antibody that inhibits interleukin (IL)-17A and IL‑17F, has demonstrated ...
Steven Daveluy, Alice Bendix Gottlieb, Matthias Augustin, Hadar Lev-Tov, Jacek Cezary Szepietowski, Barbara Horváth, Martina Lee Porter, Koremasa Hayama, Jérémy Lambert, Nicola Tilt, Bartosz Lukowski, Linnea Thorlacius   +11 more
doaj   +1 more source

Improved Pain, Morning Stiffness, and Fatigue With Bimekizumab in Axial Spondyloarthritis: Results From the Phase III BE MOBILE Studies.

OBJECTIVE: To assess the effect of bimekizumab on pain, morning stiffness, and fatigue in patients with nonradiographic and radiographic axial spondyloarthritis (axSpA) in the phase III BE MOBILE studies (ClinicalTrials.gov: NCT03928704 and NCT03928743).
Navarro-Compán, Victoria, de la Loge, Christine, Mease, Philip J., Marzo-Ortega, Helena, Walsh, Jessica A., Walsh, Jessica A, Magrey, Marina, Dougados, Maxime, Massow, Ute, Taieb, Vanessa, Deodhar, Atul, Fleurinck, Carmen, Dubreuil, Maureen, Rudwaleit, Martin, Mease, Philip, Vaux, Thomas   +15 more
core   +1 more source

Rapid and sustained improvement of psoriasis with Bimekizumab: A real‐world case series

JEADV Clinical Practice
This retrospective case series examines the efficacy and safety of Bimekizumab in 22 patients with moderate to severe plaque psoriasis in a real‐world clinical setting.
Sergio Santos‐Alarcón, Francisco Javier Mataix‐Diaz, Constantin Luca Schneller‐Pavelescu Apetrei, Isabel Belinchón‐Romero   +3 more
doaj   +1 more source

Efficacy and Safety of bimekizumab in psoriasis management in real-life: bio-naïve vs bio-experienced

: Bimekizumab is the latest monoclonal antibody approved for the management of moderate-to-severe plaque psoriasis. Currently, data investigating its use in real-life setting are limited.
Torta, Ginevra, Potestio, Luca, Bianco, Mariateresa, Megna, Matteo, Martora, Fabrizio, Ruggiero, Angelo   +5 more
core   +1 more source